CureVac to cut costs, starts GSK-partnered bird flu vaccine trial
CureVac, once a player in the Covid-19 vaccine race, announced that it plans to reduce costs across the company. It said Wednesday that 150 employees have agreed to voluntarily leave the company. The news was first reported last month by German news outlet SWR. CureVac currently has more than 1,100